×
About 5,300 results

ALLMedicine™ Cutaneous Melanoma Center

Research & Reviews  1,912 results

Rregulator CDCA8 as a potential biomarker for the prognosis of human cutaneous melanoma.
https://doi.org/10.1111/jocd.15091
Journal of Cosmetic Dermatology; Guo R, Ying J et. al.

May 17th, 2022 - Cutaneous melanoma (CM) is considered as the most malignant skin tumor with high distant metastasis and poor prognosis. Cell division cycle-associated protein (CDCA) family has a role in regulating cell proliferation, and modulating immune cell an...

Factors Related to Delayed Diagnosis of Cutaneous Melanoma in the Brazilian Public Heal...
https://doi.org/10.1007/s13187-022-02176-6 10.1097/00000658-197011000-00017 10.1097/CMR.0000000000000511 10.1200/JGO.20.00005.6 10.1186/s12913-021-06246-1 10.1097/MD.0000000000004396 10.1186/s12889-021-12324-0 10.1016/j.jaad.2020.04.137 10.1111/jdv.12896 10.5070/D3198019258 10.1111/j.1365-2133.2007.07805.x 10.1111/pde.14158 10.3322/caac.21409 10.5070/D32211033130 10.1684/ejd.2021.4171 10.1016/j.jaad.2010.12.039 10.1002/cncr.32587
Journal of Cancer Education : the Official Journal of The... Paula Bhering Nogueira A, Drummond-Lage AP et. al.

May 17th, 2022 - In Brazil, 75% of the population uses the Sistema Único de Saúde (SUS), public health system, where the general practitioner (GP) is responsible for melanoma diagnosis. Identify the factors related to the delay in diagnosing melanoma patients assi...

European consensus-based interdisciplinary guideline for melanoma. Part 1: Diagnostics:...
https://doi.org/10.1016/j.ejca.2022.03.008
European Journal of Cancer (Oxford, England : 1990); Garbe C, Amaral T et. al.

May 16th, 2022 - Cutaneous melanoma (CM) is potentially the most dangerous form of skin tumor and causes 90% of skin cancer mortality. A unique collaboration of multi-disciplinary experts from the European Dermatology Forum (EDF), the European Association of Derma...

Association between hypertension and cutaneous melanoma, and the effect of aspirin: ext...
https://doi.org/10.1016/j.canep.2022.102173
Cancer Epidemiology; Yan MK, Orchard SG et. al.

May 15th, 2022 - The association between hypertension and melanoma is unclear, and previous analyses of data from the ASPirin in Reducing Events in the Elderly (ASPREE) study demonstrated a reduced number of invasive melanoma events amongst aspirin-exposed hyperte...

Case report: response to the ERK1/2 inhibitor ulixertinib in BRAF D594G cutaneous melan...
https://doi.org/10.1097/CMR.0000000000000830
Melanoma Research; Wolfe Z, Friedland JC et. al.

May 14th, 2022 - Melanoma is characterized by oncogenic mutations in pathways regulating cell growth, proliferation, and metabolism. Greater than 80% of primary melanoma cases harbor aberrant activation of the mitogen-activated protein kinase kinase/extracellular-...

see more →

Guidelines  8 results

SEOM clinical guideline for the management of cutaneous melanoma (2020).
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8057998
Clinical & Translational Oncology : Official Publication ... Majem M, Manzano JL et. al.

Mar 3rd, 2021 - Melanoma affects about 6000 patients a year in Spain. A group of medical oncologists from Spanish Society of Medical Oncology (SEOM) and Spanish Multidisciplinary Melanoma Group (GEM) has designed these guidelines to homogenize the management of t...

Systemic Therapy for Melanoma: ASCO Guideline.
https://doi.org/10.1200/JCO.20.00198
Journal of Clinical Oncology : Official Journal of the Am... Seth R, Messersmith H et. al.

Apr 2nd, 2020 - To provide guidance to clinicians regarding the use of systemic therapy for melanoma. ASCO convened an Expert Panel and conducted a systematic review of the literature. A systematic review, one meta-analysis, and 34 additional randomized trials we...

Guidelines of care for the management of primary cutaneous melanoma.
https://doi.org/10.1016/j.jaad.2018.08.055
Journal of the American Academy of Dermatology; Swetter SM, Tsao H et. al.

Nov 6th, 2018 - The incidence of primary cutaneous melanoma continues to increase each year. Melanoma accounts for the majority of skin cancer-related deaths, but treatment is usually curative following early detection of disease. In this American Academy of Derm...

An update on the Society for Immunotherapy of Cancer consensus statement on tumor immun...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5977556
Journal for Immunotherapy of Cancer; Sullivan RJ, Atkins MB et. al.

Jun 1st, 2018 - Cancer immunotherapy has been firmly established as a standard of care for patients with advanced and metastatic melanoma. Therapeutic outcomes in clinical trials have resulted in the approval of 11 new drugs and/or combination regimens for patien...

New NCCN Guidelines for Uveal Melanoma and Treatment of Recurrent or Progressive Distan...
https://doi.org/10.6004/jnccn.2018.0042
Journal of the National Comprehensive Cancer Network : JN... Barker CA, Salama AK

May 23rd, 2018 - The NCCN Guidelines Panel for Melanoma debuted new guidelines for uveal melanoma at the NCCN 23rd Annual Conference. Although uveal melanoma and cutaneous melanoma share the same name, they do have different characteristics and treatments. The NCC...

see more →

Drugs  1 results see all →

Clinicaltrials.gov  46 results

Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions
https://clinicaltrials.gov/ct2/show/NCT03947385

May 12th, 2022 - This is a Phase 1/2, multi-center, open-label basket study designed to evaluate the safety and anti-tumor activity of IDE196 in patients with solid tumors harboring GNAQ or GNA11 (GNAQ/11) mutations or PRKC fusions, including metastatic uveal mela...

Study of Ipilimumab, Nivolumab, and Cabozantinib in Patients With Cutaneous Melanoma
https://clinicaltrials.gov/ct2/show/NCT05200143

May 9th, 2022 - This is a phase II, single arm, single institution clinical trial. Eligible adults with anti-PD-1 refractory, unresectable/metastatic cutaneous melanoma will be treated with the triplet combination of ipilimumab 1 mg/kg + nivolumab 3 mg/kg every 3...

Isolated Hepatic Perfusion in Combination With Ipilimumab and Nivolumab in Patients With Uveal Melanoma Metastases
https://clinicaltrials.gov/ct2/show/NCT04463368

May 4th, 2022 - Uveal melanoma is the most common primary intraocular malignancy in adults. Despite successful control of the primary tumour, metastatic disease will develop in approximately 35%-50% of the patients within 10 years. The liver is the most common si...

Nemvaleukin Alfa (ALKS 4230) Monotherapy in Patients With Advanced Cutaneous Melanoma or Advanced Mucosal Melanoma - ARTISTRY-6
https://clinicaltrials.gov/ct2/show/NCT04830124

May 4th, 2022 - This study observes the antitumor activity, safety, tolerability, PK, and pharmacodynamics in patients with inoperable and/or metastatic melanoma following prior anti-PD-[L]-1 therapy

Sun Exposure of Outdoor Workers in Mayotte and Reunion Island
https://clinicaltrials.gov/ct2/show/NCT05336422

Apr 20th, 2022 - The UV index in Mayotte and Reunion is greater than 14, eight months out of twelve. This index decreases linearly over the period from mid-April to mid-August where it can drop to reach an index of 8 in July. The inhabitants are therefore exposed ...

see more →

News  153 results

BRAF V600E Expression in Primary Melanoma and Its Association With Death: A Population-Based, Retrospective, Cross-Sectional Study
https://www.mdedge.com/dermatology/article/254405/melanoma/braf-v600e-expression-primary-melanoma-and-its-association-death
Jamison A. Harvey, MD, Julia S. Lehman, MD et. al.

May 6th, 2022 - Approximately 50% of melanomas contain BRAF mutations, which occur in a greater proportion of melanomas found on sites of intermittent sun exposure. 1BRAF-mutated melanomas have been associated with high levels of early-life ambient UV exposure, es.

Administration of RP1 Through Intratumoral Injection Offers Unique Advantages in Melanoma Treatment
https://www.onclive.com/view/administration-of-rp1-through-intratumoral-injection-offers-unique-advantages-in-melanoma-treatment

Apr 26th, 2022 - Oncolytic immunotherapy with talimogene laherparepvec (T-VEC; Imlygic) and vusolimogene oderparepvec (RP1) has the potential to provide unique clinical benefits in patients with melanoma through direct intratumoral administration, according to Nik...

Global Melanoma Incidence High and on the Rise
https://www.medscape.com/viewarticle/971652

Apr 5th, 2022 - Even by cautious calculations, the worldwide incidence of cutaneous melanoma is high and predicted to rise sharply over the next 2 decades, cancer epidemiologists warn. An estimated 325,000 people worldwide received a new diagnosis of cutaneous me...

Complex Link Between Gut Microbiome and Immunotherapy Response in Advanced Melanoma
https://www.medscape.com/viewarticle/969787

Mar 7th, 2022 - A large-scale meta-analysis has verified that the gut microbiome does influence patients' response to immune checkpoint inhibitor (ICI) therapy in advanced melanoma, but the relationship appears to be more complex than previously thought. Overall,...

Fast Five Quiz: Genetic/Biomarker Testing in Melanoma
https://www.medscape.com/viewarticle/966637

Feb 22nd, 2022 - Malignant melanoma is the fifth most common cancer, with an estimated 106,110 new cases in the United States in 2021. The incidence of malignant melanoma has been on the rise globally and trails only lung cancer in women in terms of the rate of in...

see more →